Motif Bio will be presenting two poster studies at IDWeek, October 26 to 30 in New Orleans
OREANDA-NEWS. Motif Bio plc (AIM: MTFB), the clinical stage biopharmaceutical company specialising in developing novel antibiotics, announces that it will be presenting two poster studies at IDWeek, October 26 to 30 in New Orleans, USA.
IDWeek is an annual gathering of 6,000 practitioners who are members of the Infectious Disease Society of America (IDSA), the Society for Healthcare Epidemiology of America (SHEA), the HIV Medicine Association (HIVMA) and the Pediatric Infectious Diseases Society (PIDS) and represents the largest gathering of practicing professionals dedicated to the treatment, control and eradication of infectious diseases.
Motif Bio will be presenting two posters at the session titled 'Antimicrobial Pharmacokinetics and Pharmacodynamics' on Saturday, October 29, 2016 between 12.30 and 2.00 pm.
The first poster is titled 'The Use of PK/PD Systems Analyses to Determine the Optimal Fixed Dosing Regimen of Iclaprim (ICL) for a Phase III ABSSSI Clinical Trial'.
The second poster is titled 'A 2012-2014 Global Antimicrobial Surveillance of Iclaprim Against Clinical Strains Causing Hospital-Associated Bacterial Pneumonia (HABP) and Skin and Skin Structure Infections (SSSI)'.
Following the conclusion of the conference, both poster presentations will be made available on the Company website: www.motifbio.com
About Motif Bio
Motif Bio is a clinical-stage biopharmaceutical company, engaged in the research and development of novel antibiotics designed to be effective against serious and life-threatening infections in hospitalized patients caused by multi-drug resistant bacteria. Our lead product candidate, iclaprim, is being developed for the treatment of acute bacterial skin and skin structure infections (ABSSSI) and hospital acquired bacterial pneumonia (HABP), including ventilator associated bacterial pneumonia (VABP), which is often caused by MRSA (methicillin resistant Staphylococcus aureus). We are currently enrolling and dosing patients in two global Phase 3 clinical trials with an intravenous formulation of iclaprim, for the treatment of ABSSSI, which are expected to be completed in 2017.
The ID Week partners:
The Infectious Diseases Society of America (IDSA) represents physicians, scientists and other health care professionals who specialize in infectious diseases. IDSA's purpose is to improve the health of individuals, communities, and society by promoting excellence in patient care, education, research, public health, and prevention relating to infectious diseases. www.idsociety.org
The Society for Healthcare Epidemiology of America (SHEA) is a professional society representing physicians and other healthcare professionals around the world with expertise in healthcare epidemiology and infection prevention and control. SHEA's mission is to prevent and control healthcare-associated infections and advance the field of healthcare epidemiology. www.shea-online.org